Second Sight Medical Products Inc. (NASDAQ:EYES) dropped 3.1% during mid-day trading on Tuesday . The company traded as low as $3.79 and last traded at $3.79, with a volume of 67,836 shares trading hands. The stock had previously closed at $3.91.

EYES has been the topic of a number of recent research reports. Zacks Investment Research downgraded Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Monday, April 18th. Rodman & Renshaw restated a “buy” rating and set a $16.00 price objective on shares of Second Sight Medical Products in a report on Tuesday, July 26th.

The stock’s market capitalization is $159.93 million. The firm’s 50-day moving average price is $3.92 and its 200-day moving average price is $4.44.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. During the same period last year, the company earned ($0.12) earnings per share. The company had revenue of $1.04 million for the quarter, compared to analysts’ expectations of $2.66 million. The business’s revenue for the quarter was down 63.0% on a year-over-year basis. Equities analysts predict that Second Sight Medical Products Inc. will post ($0.62) earnings per share for the current year.

In other Second Sight Medical Products news, Chairman Robert J. Greenberg sold 8,571 shares of Second Sight Medical Products stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total transaction of $35,141.10. Following the completion of the sale, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.